Results 71 to 80 of about 187,458 (237)

Additional file 1: Table S1. of Highly selective inhibition of Brutonâ s tyrosine kinase attenuates skin and brain disease in murine lupus

, 2018
Antibodies utilized for choroid plexus flow cytometric analysis. (DOCX 12 kb)
Chalmers, Samantha, Wen, Jing, Doerner, Jessica, Stock, Ariel, Cuda, Carla, Makinde, Hadijat, Perlman, Harris, Bosanac, Todd, Webb, Deborah, Nabozny, Gerald, Fine, Jay, Klein, Elliott, Ramanujam, Meera, Putterman, Chaim   +13 more
openaire   +1 more source

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib [PDF]

, 2017
The Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side-effects of ibrutinib.
Appleby, Niamh, Bruce, David, Bye, Alex P., Desborough, Michael J., Gibbins, Jon M., Hildyard, Catherine A. T., Hughes, Craig E., Kriek, Neline, Nock, Sophie H., Sage, Tanya, Unsworth, Amanda J.   +10 more
core   +2 more sources

Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.

Journal of Medicinal Chemistry, 2019
Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by ...
R. Caldwell, Hui Qiu, B. Askew, Andrew T. Bender, N. Brugger, M. Camps, M. Dhanabal, Vikram Dutt, T. Eichhorn, A. Gardberg, A. Goutopoulos, R. Grenningloh, J. Head, B. Healey, Brian L. Hodous, B. Huck, Theresa L. Johnson, Christopher Jones, Reinaldo C Jones, I. Mochalkin, F. Morandi, Ngan Nguyen, M. Meyring, Justin R. Potnick, Dusica Santos, R. Schmidt, B. Sherer, A. Shutes, K. Urbahns, A. Follis, A. Wegener, S. Zimmerli, L. Liu-Bujalski   +32 more
semanticscholar   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Additional file 2: Figure S1. of Highly selective inhibition of Brutonâ s tyrosine kinase attenuates skin and brain disease in murine lupus

, 2018
Flow cytometry gating strategy. Cortical and choroid plexus tissue from MRL/lpr mice treated or not with BI-BTK-1 were analyzed by flow cytometric analysis. Red arrows denote sequential gated population (red boxes). Black arrows denote sequential non-gated population. (DOCX 358 kb)
Chalmers, Samantha, Wen, Jing, Doerner, Jessica, Stock, Ariel, Cuda, Carla, Makinde, Hadijat, Perlman, Harris, Bosanac, Todd, Webb, Deborah, Nabozny, Gerald, Fine, Jay, Klein, Elliott, Ramanujam, Meera, Putterman, Chaim   +13 more
openaire   +1 more source

The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis. [PDF]

, 2018
Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy with a variable clinical outcome. Biomarkers of CLL progression are required for optimising prognosis and therapy.
Albano, F., Chiurazzi, F., Cimmino, C., Fiume, G., Frieri, C2, Golino, G., Iaccino, E., Mallardo, M., Mimmi, S., Pastore, A., Pisano, A., Quinto, I., Scala, G., Vecchio, E.   +13 more
core   +2 more sources

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, EarlyView.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source

Additional file 1: Table S1. of HM71224, a novel Brutonâ s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

, 2016
Sequence alignment of kinases. Table S2. Arthritis score and body weight during treatment period. Figure S1. Experimental design of collagen-induced arthritis. Figure S2. Effect of HM71224 on EGFR signaling. Figure S3. HM71224 inhibits Btk phosphorylation. Figure S4. HM71224 inhibits osteoclastogenesis. Figure S5.
Park, Jin, Joo-Yun Byun, Park, Ji, Yu-Yon Kim, Lee, Ye, Oh, Jeong, Jang, Sun, Kim, Young, Song, Yeong, Jeewoong Son, Kwee Suh, Lee, Young-Mi, Lee, Eun   +12 more
openaire   +1 more source

Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis.

Journal of Clinical Investigation, 2020
No known therapies can prevent anaphylaxis. Bruton's tyrosine kinase (BTK) is an enzyme thought to be essential for high-affinity IgE receptor (FcεRI) signaling in human cells.
M. Dispenza, Rebecca A. Krier-Burris, K. Chhiba, B. Undem, Piper A. Robida, B. Bochner   +5 more
semanticscholar   +1 more source

Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis

Journal of Clinical Medicine, 2022
Bruton’s tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells ...
N. Garg, Elizabeth Padron, K. Rammohan, Courtney F Goodman   +3 more
semanticscholar   +1 more source